This edition presents key opinion leader (KOL) views on recent developments in the moderate to severe psoriasis treatment market. Topics covered include: Janssen Biotech announcing new data from two pivotal Phase III studies reporting the efficacy and safety of guselkumab (anti-IL23 monoclonal antibody [mAb]) in the treatment of adults with moderate to severe plaque psoriasis; Sun Pharmaceutical announcing new data from two pivotal Phase III clinical trials of tildrakizumab, an investigational anti-IL23/p19 mAb being evaluated for the treatment of moderate-to-severe plaque psoriasis; Eli Lilly announcing new data from the Phase III IXORA-S study; and Merck KGaA and Ablynx reporting positive early-stage results for ALX-0761, a trivalent, bi-specific nanobody that blocks both IL-17A and IL-17F.
How impressed are KOLs by the efficacy data from the VOYAGE 2 and NAVIGATE studies for guselkumab, and what could this do to support approval and future uptake?
Do KOLs have any concerns about the design of the VOYAGE 2 and NAVIGATE studies?
What are the primary advantages of using guselkumab; efficacy, dosing or both?
Where will guselkumab be used in the psoriasis treatment paradigm, or is it too early to tell?
What could get in the way of guselkumab’s evolution as the gold-standard treatment for moderate to severe psoriasis?
How did KOLs react to the data from the reSURFACE 1 and 2 studies for tildrakizumab, and will this data limit or drive uptake as a treatment for psoriasis?
Do KOLs have any issues with the design of tildrakizumab’s clinical studies, including patient selection and dosing? If so, what could be the potential impact on future uptake?
Will tildrakizumab’s lack of differentiation limit its uptake, or do KOLs welcome the addition of a ‘softer’ treatment option?
Where in the treatment paradigm will tildrakizumab be used?
Does positive data from the IXORA-S study add anything new to ixekizumab’s story, or does it simply cement its position in the treatment paradigm?
What will be the key reason physicians prescribe ixekizumab over other treatment options: safety, efficacy, patient access or something else?
Where in the treatment paradigm will ixekizumab be used?
How did KOLs react to the early stage data for ALX-0761?
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.